Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin from pancreatic beta cells after eating. It drives weight loss through satiety and slowed gastric emptying, not anabolic pathways, and does not affect testosterone, muscle building, or athletic performance. Monotherapy weight loss is modest (~9-11%); the headline results come from the CagriSema combination with semaglutide. Rated 3 as a satiety-hormone analog working through natural appetite pathways, in line with other GLP-1-era weight agents.
Overview
A long-acting amylin analog developed by Novo Nordisk. Amylin is a satiety hormone released alongside insulin after meals, and it works through a different pathway than GLP-1, so cagrilintide complements GLP-1 agonists rather than duplicating them. It is best known as the amylin half of CagriSema, the fixed-dose once-weekly combination of cagrilintide 2.4mg and semaglutide 2.4mg, which produced 22.7% mean weight loss at 68 weeks in the REDEFINE 1 trial assuming full adherence (the treatment-policy estimate, which counts everyone regardless of adherence, was 20.4%).
Important Warnings
- •GLP-1/amylin class agents are contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2)
- •Rapid weight loss causes meaningful lean-mass (muscle) loss unless protein intake is high and resistance training is maintained
- •Rebound weight gain is common after discontinuation without sustained lifestyle change
- •Stacking cagrilintide with GLP-1/GIP/glucagon agonists beyond the validated CagriSema combo multiplies GI, dehydration and muscle-loss risk
- •Monotherapy is investigational. Long-term safety data outside trials is limited
Purpose & Use Cases
Appetite Suppression
Amylin-receptor agonism promotes satiety and slows gastric emptying, reducing food intake through a pathway separate from GLP-1.
Weight Loss
Monotherapy produced ~9.1% weight loss at 2.4mg and ~10.8% at 4.5mg over 26 weeks in Phase 2. As part of CagriSema it contributes to ~22.7% mean loss at 68 weeks.
GLP-1 Combination (CagriSema)
Designed to be paired with semaglutide. The amylin + GLP-1 combination outperforms either agent alone (22.7% vs 16.1% for semaglutide and 11.8% for cagrilintide in REDEFINE 1).
Benefits
- Distinct amylin mechanism that stacks with GLP-1 agonists
- Strong combination results as CagriSema (~22.7% mean weight loss at 68 weeks)
- Once-weekly subcutaneous dosing
- Generally well tolerated at lower doses
- Improves multiple metabolic markers alongside weight loss
Good to Know
Amylin, not GLP-1
Cagrilintide is an amylin analog, a different satiety hormone from GLP-1. That is precisely why it is combined with semaglutide, two mechanisms, two receptors, additive appetite suppression rather than redundancy.
CagriSema is the real product
On its own cagrilintide is a moderate weight-loss agent (~9-11%). The clinically important entity is CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg), which reached ~22.7% mean weight loss at 68 weeks in REDEFINE 1 and was filed with the FDA in December 2025.
Lean-mass loss during rapid weight loss
Like all satiety-driven agents, a substantial fraction of weight lost can be lean tissue if intake and training are not managed. High protein plus resistance training is what shifts the fat-to-lean loss ratio in your favor. This matters for anyone using it in a physique context.
No anabolic or hormonal action
It does not raise or suppress testosterone, does not aromatize, and has no effect on the HPTA. There is no AI or PCT consideration. It is purely a metabolic/appetite tool.
Rebound weight is the norm
Appetite returns after stopping. Without established dietary and training habits, weight regain is expected. The drug manages appetite, it does not permanently reset the setpoint.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 0.3 – 0.6 mg/week |
| Intermediate | 1.2 – 2.4 mg/week |
| Advanced | 2.4 – 4.5 mg/week |
In the Phase 2 monotherapy dose-finding trial, target doses of 0.3, 0.6, 1.2, 2.4 and 4.5mg once weekly were each reached via a dose-escalation period of up to 6 weeks to limit nausea. In the CagriSema combination it is fixed at 2.4mg alongside semaglutide 2.4mg, with both components titrated together over roughly 16 weeks (0.25 -> 0.5 -> 1.0 -> 1.7 -> 2.4mg, ~4-week steps) before reaching maintenance. Slow titration is the key to tolerability; compounded/research-chemical cagrilintide is commonly dosed and titrated on this same schedule.
Side Effects
Nausea
very commonThe most common side effect, driven by delayed gastric emptying and central satiety signaling. Usually worst during titration and eases with time.
Slow titration; smaller meals; avoid fatty foods; stop eating when satisfied.
Vomiting
commonCan occur with rapid dose increases or overeating.
Slow titration; do not push past satiety.
Constipation
commonSlowed GI motility can cause constipation.
Fiber, adequate hydration, movement.
Diarrhea
uncommonGI disturbance reported in a minority of users.
Usually transient; stay hydrated.
Injection Site Reactions
uncommonMild redness, itching or swelling at the injection site.
Rotate injection sites.
General Mitigation Strategies
GI side effects are dose-dependent and improve with continued use. Titrate slowly, eat smaller meals, and stay well hydrated. As with all rapid weight-loss agents, keep protein intake high and train with resistance to protect lean mass. Discontinue and seek care for severe persistent abdominal pain.
Support Supplements
Ancillary supplements commonly run alongside Cagrilintide to manage side effects, support the target tissue, or fill nutrient demands it creates.
High Protein Intake
KeyRapid appetite suppression makes it easy to under-eat protein, accelerating lean-mass loss. Adequate protein is the single most important lever for preserving muscle during weight loss.
- Dose
- 1.6-2.2 g per kg bodyweight per day
- Timing
- Spread across meals; prioritize protein first when appetite is low
Resistance Training
KeyThe strongest stimulus for preserving (or building) lean mass in a caloric deficit. Weight lost without training is a higher fraction muscle. Not a supplement, but the essential companion protocol.
- Timing
- 2-4 sessions per week, progressive overload
Creatine Monohydrate
Supports strength and lean-mass retention during a deficit; cheap and well-evidenced.
- Dose
- 3-5 g daily
- Timing
- Any time, daily and consistent
Electrolytes & Fiber
Reduced food intake lowers electrolyte and fiber intake; supports GI comfort, hydration and constipation prevention.
- Dose
- Sodium/potassium/magnesium to appetite; 25-35 g fiber/day
- Timing
- Daily
Semaglutide (as CagriSema)
Cagrilintide is designed to be paired with a GLP-1. The validated combination is CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg), which markedly outperforms either agent alone.
- When
- This is the intended clinical use of cagrilintide. Combining incretin/satiety agents raises GI and dehydration risk, titrate carefully.
Post Cycle Therapy (PCT)
Not hormonal (in the anabolic sense). Does not affect the HPTA. No PCT required. Weight regain is common after stopping unless habits are maintained.
How It Works
Cagrilintide is an acylated (fatty-diacid) analog of human amylin that acts as an agonist at the amylin and calcitonin receptors. Native amylin is released with insulin from pancreatic beta cells and reduces food intake by slowing gastric emptying, suppressing glucagon, and promoting satiety via the area postrema in the brainstem. Because amylin signaling is distinct from and complementary to GLP-1 signaling, combining cagrilintide with semaglutide (CagriSema) engages two separate satiety systems for additive weight loss. The fatty-diacid acylation gives it a ~7-8 day half-life, enabling once-weekly dosing.
Fundamentals
Reference on the practices relevant to Cagrilintide: how they are done and where they go wrong. Not a recommendation to use it.
Legal Status
Investigational. Not FDA-approved as monotherapy for any indication. Novo Nordisk submitted an NDA for the fixed-dose combination CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) to the FDA on December 18, 2025; as of mid-2026 the application remains under review with a decision expected later in 2026. Standalone cagrilintide is sourced as a research chemical/compounded product outside of any approved clinical pathway.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
Cagrilintide is not explicitly named on the WADA Prohibited List. GLP-1 agonists (semaglutide, tirzepatide) sit on WADA's Monitoring Program as approved prescription drugs, but cagrilintide monotherapy has no approval from any regulatory health authority, which is exactly the condition WADA's S0 (Non-Approved Substances) category targets ("prohibited at all times... with no current approval by any governmental regulatory health authority for human therapeutic use"). That makes standalone cagrilintide a real S0 risk for tested athletes even though it is not named individually. Status is genuinely uncertain; verify before competition.
References
- REDEFINE 1: Cagrilintide-Semaglutide in Overweight/Obesity - NEJM
- Cagrilintide-Semaglutide in Overweight/Obesity and Type 2 Diabetes - NEJM
- Novo Nordisk files for FDA approval of CagriSema (Dec 2025)
- Lau et al. 2021 - Once-weekly cagrilintide for weight management: Phase 2 dose-finding trial (Lancet) - PubMed